2014 Congress

Viral Hepatitis Congress 2014
Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt, Germany
9–11 October 2014

Scientific Programme*
Webcast
Posters
Abstracts*

* Opens in new window

Webcast

Accessing the webcast on a PC
Click the link [PC]

Recommended specifications to avoid play back issues:
Internet Explorer 7 or above
Screen resolution of 1024 x 768 or higher
Internet bandwidth of 750 kbps or higher

Accessing the webcast on a Mac
Click the link [MAC]

Recommended specifications to avoid play back issues:
Mac OS X 10.4.8 or later
Safari 2.0.4 or later
Screen resolution of 1024 x 768 or higher
Internet bandwidth of 750 kbps or higher

All presentations open in a new window.


Thursday 9 October

Opening
Ira Jacobson (New York, USA); Stefan Zeuzem (Frankfurt, Germany)
[PC] [MAC]

Special Opening Lecture
Keeping blood safe – a global challenge
Harvey J Alter (Bethesda, USA)
[PC] [MAC]

Screening and diagnosis: what you need to know

Non-invasive assessment of liver fibrosis
Nezam Afdhal (Boston, USA)
[PC] [MAC]

HCV genome sequencing: what the clinician needs to know
Christoph Sarrazin (Frankfurt, Germany)
[PC] [MAC]

Interactive Q&A and panel discussion
[PC] [MAC]

Keynote Lecture

The risk of developing cancer following successful treatment for hepatitis
Massimo Colombo (Milan, Italy)
[PC] [MAC]

Association of the −515A>G CDC6 polymorphism with risk to develop hepatocellular carcinoma in patients with chronic hepatitis C
Mohammed Elhendawy (Tanta, Egypt)
Oral presentation, selected from submitted abstracts
[PC] [MAC]

Hepatitis C treatment: the story so far

Drug availability: what, where, and when?
Graham Foster (London, UK)
[PC] [MAC]

Global differences: what can we learn from HIV?
Robert Schooley (San Diego, USA)
[PC] [MAC]

Boceprevir and telaprevir: what have we learned?
Marc Bourlière (Marseille, France)
[PC] [MAC]

Interactive Q&A and panel discussion
[PC] [MAC]

Friday 10 October

Hepatitis C treatment: the way forward

With Interferon
Michael Fried (North Carolina, USA)
[PC] [MAC]

Simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in HCV genotype 1-infected patients: the Phase III ATTAIN study
Holger Hinrichsen (Kiel, Germany)
Oral presentation, selected from submitted abstract
[PC] [MAC]

Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results
Ira Jacobson (New York, USA)
Oral presentation, selected from submitted abstract
[PC] [MAC]

Without Interferon, with nucs
David Nelson (Gainesville, USA)
[PC] [MAC]

Interactive Q&A and panel discussion
[Awaiting]

Interferon-free Direct-Acting Antiviral (DAA) regimens without nucleoside (tide) analogs for treatment of chronic hepatitis C
Kris Kowdley (Seattle, USA)
[Awaiting]

Treating decompensated cirrhotics
Geoffrey Dusheiko (London, UK)
[PC] [MAC]

Treating patients before and after transplant
Marina Berenguer (Valencia, Spain)
[PC] [MAC]

New DAAs and drug-drug interactions
David Burger (Nijmegen, Netherlands)
[PC] [MAC]

Interactive Q&A and panel discussion
[PC] [MAC]

Real-life examples, a case-study session

Real-life examples: transplantation
Marina Berenguer (Valencia, Spain)
[PC] [MAC]

Real-life examples: HIV co-infection
Jürgen Rockstroh (Bonn, Germany)
[PC] [MAC]

Real-life examples: renal impairment
Paul Martin (Miami, Florida)
[PC] [MAC]

Interactive Q&A and panel discussion
[PC] [MAC]

Hepatitis B treatment

Long-term persistence of patient-derived hepatitis B virus infection in 3D microfluidic primary hepatocyte cultures
Marcus Dorner (London, UK)
Oral presentation, selected from submitted abstracts
[PC] [MAC]

Entecavir vs the Tenofovirs (TDF and TAF)
Harry Janssen (Toronto, Canada)
[PC] [MAC]

Interferon and add-on strategies in the treatment of chronic hepatitis B
Tarik Asselah (Paris, France)
[PC] [MAC]

Preventing reactivation in immunosuppressive and chemotherapy patients
Maria Buti (Barcelona, Spain)
[PC] [MAC]

An investigation of genome-wide promoter region CpG island methylation profiles in patients with chronic hepatitis B virus infection
Mankgopo Kgatle (Cape Town, South Africa)
Oral presentation, selected from submitted abstracts
[PC] [MAC]

Interactive Q&A and panel discussion
[PC] [MAC]

Saturday 11 October

Keynote Lecture

Understanding HCV disease progression and the associated cost
Uwe Siebert (Hall in Tirol, Austria)
[PC] [MAC]

Debating the treatment of HCV

Treating genotypes 3 and 4 patients with/without IFN or a second DAA
Tarik Asselah (Paris, France)
[PC] [MAC]

How should we monitor patients after SVR?
Ira Jacobson (New York, USA)
[PC] [MAC]

How do we treat acute HCV when we don’t have any trial data?
Heiner Wedemeyer (Hannover, Germany)
[PC] [MAC]

HCV contributes to the aggravation suppressive activity of natural regulatory T cells and induces the emergence of type 1 regulatory T cells
Laurissa Ouaguia (Lille, France)
Oral presentation, selected from submitted abstracts
[PC] [MAC]

Interactive Q&A and panel discussion
[PC] [MAC]

The effect of hepatitis B and C outside the liver

HCV and insulin resistance
Francesco Negro (Geneva, Switzerland)
[PC] [MAC]

HCV and Lymphomas
Jordan Feld (Toronto, Canada)
[PC] [MAC]

Vasculitis and its relationship to hepatitis C
Francesco Dammacco (Bari, Italy)
[PC] [MAC]

Interactive Q&A and panel discussion
[PC] [MAC]

Keynote Lecture

Unresolved issues in HCV biology
Darius Moradpour (Lausanne, Switzerland)
[PC] [MAC]

Closing
Stefan Zeuzem (Frankfurt, Germany)
[PC] [MAC]

Posters

Poster presentations are available as interactive, page-turning books, these files (which open in a new window) require the latest version of Flash Player to be viewed. You can view the posters as a downloadable PDF. Click here to access the PDF (13.2MB), which will also open in a new window.

Book 1
HEPATITIS C VIRUS – Natural history and epidemiology [O314, P3-P4]
HEPATITIS C VIRUS – Treatment and late-stage clinical trials (Phase IIb, Phase III and Phase IV) [O213, P7-P10]

Book 2
HEPATITIS C VIRUS – Practical management strategies [P11-P13]
HEPATITIS C VIRUS – Treatment monitoring and predictors of therapeutic response [P14-P16]
HEPATITIS C VIRUS – Preclinical and early clinical development (Phase I and Phase IIa) [P20]
HEPATITIS C VIRUS – Molecular biology and characterisation [P22]
HEPATITIS C VIRUS – Other [P23-P26]

Book 3
HEPATITIS B VIRUS – Diagnosis and monitoring [P27]
HEPATITIS B VIRUS – Natural history and epidemiology [P28]
HEPATITIS B VIRUS – Treatment and late-stage clinical trials (Phase IIb, Phase III and Phase IV) [P30]
HEPATITIS B VIRUS – Molecular biology and characterisation [P33-P34]
HEPATITIS B VIRUS – Other [O235, P35-P37]

Book 4
HEPATOCELLULAR CARCINOMA [O113, P38]
PHARMACOKINETICS AND DRUG INTERACTIONS [P39-P41]
TRANSPLANTATION AND VIRAL HEPATITIS [P44]
VIRAL HEPATITIS A, D AND E [P47-P49]